It is a protein vaccine, different from the anti-Covid vaccines already authorized in the EU. And there were those who were anxiously waiting for him. For example, several people reluctant to give in to the shield injection claim that they would accept this vaccine. Now Novavax collects the green light from the European Medicines Agency EMA for its vaccine that will be administered “via two injections, usually into the muscle of the upper arm, 3 weeks apart”, he explains. EU regulatory body. The ‘ingredients’ of Nuvaxovid * (this is the name of the upcoming new entry in the vaccination campaigns of Europe) are a laboratory-made version of the Spike protein found on the surface of the virus, and an ‘adjuvant’, a substance that helps to strengthen the immune response to the vaccine.
With these weapons, the new vaccine promises to build the anti-Covid shield. Here’s how it works: When Nuvaxovid is administered, the immune system identifies the protein as foreign and makes natural defenses – antibodies and T cells – against it. If the vaccinated person later comes into contact with the Sars-CoV-2 coronavirus, the immune system will recognize the Spike protein on the virus and be ready to attack it. Antibodies and immune cells can protect against Covid by working together to kill the virus, prevent its entry into cells and destroy infected cells.
#Novavax #Ema #protein #vaccine #works